Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2024-04-21 , DOI: 10.1111/apt.18000
Stephanie A. Vuijk ₁ , Maria M. E. Jongsma ₁ , Britt M. Hoeven ₁ , Maarten A. Cozijnsen ₁ , Merel van Pieterson ₁ , Tim G. J. de Meij ₂ , Obbe F. Norbruis ₃ , Michael Groeneweg ₄ , Victorien M. Wolters ₅ , Herbert van Wering ₆ , Thalia Hummel ₇ , Janneke Stapelbroek ₈ , Cathelijne van der Feen ₉ , Patrick F. van Rheenen ₁₀ , Michiel P. van Wijk ₂ , Sarah Teklenburg ₃ , Dimitris Rizopoulos _{11,

12} , Marten J. Poley _{13,

14} , Johanna C. Escher ₁ , Lissy de Ridder ₁

Affiliation

Department of Paediatric Gastroenterology Erasmus Medical Center/Sophia Children's Hospital Rotterdam The Netherlands
Department of Paediatric Gastroenterology, Emma Children's Hospital Amsterdam UMC, VU University Amsterdam The Netherlands
Department of Paediatric Gastroenterology Isala Hospital Zwolle The Netherlands
Department of Paediatric Gastroenterology Maasstad Hospital Rotterdam The Netherlands
Department of Paediatric Gastroenterology UMC Utrecht/Wilhelmina Children's Hospital Utrecht The Netherlands
Department of Paediatric Gastroenterology Amphia Hospital Breda The Netherlands
Department of Paediatric Gastroenterology Medical Spectrum Twente Enschede The Netherlands
Department of Paediatric Gastroenterology Catharina Hospital Eindhoven The Netherlands
Department of Paediatric Gastroenterology Jeroen Bosch Hospital 's Hertogenbosch The Netherlands
Department of Paediatric Gastroenterology University Medical Center, University of Groningen Groningen The Netherlands
Department of Biostatistics Erasmus MC Rotterdam The Netherlands
Department of Epidemiology Erasmus MC Rotterdam The Netherlands
Institute for Medical Technology Assessment and Erasmus School of Health Policy & Management Erasmus University Rotterdam Rotterdam The Netherlands
Department of Pediatric Surgery and Intensive Care Erasmus Medical Center/Sophia Children's Hospital Rotterdam The Netherlands

Data on cost-effectiveness of first-line infliximab in paediatric patients with Crohn's disease are limited. Since biologics are increasingly prescribed and accompanied by high costs, this knowledge gap needs to be addressed.

中文翻译：